Longitude Capital Associates, L.P.'s Net Worth
$459 Million
Who is Longitude Capital Associates, L.P.?
Longitude Capital Associates, L.P. has an estimated net worth of $459 Million. This is based on reported shares across multiple companies, which include CORCEPT THERAPEUTICS INC, COLLEGIUM PHARMACEUTICAL, INC, and Esperion Therapeutics, Inc..
SEC CIK
Longitude Capital Associates, L.P.'s CIK is 0001430719
Past Insider Trading and Trends
2015 was Longitude Capital Associates, L.P.'s most active year for acquiring shares with 10 total transactions. Longitude Capital Associates, L.P.'s most active month to acquire stocks was the month of February. 2014 was Longitude Capital Associates, L.P.'s most active year for disposing of shares, totalling 26 transactions. Longitude Capital Associates, L.P.'s most active month to dispose stocks was the month of October. 2015 saw Longitude Capital Associates, L.P. paying a total of $12,133,536.06 for 6,439,904 shares, this is the most they've acquired in one year. In 2017 Longitude Capital Associates, L.P. cashed out on 1,000,000 shares for a total of $17,340,000.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
COLLEGIUM PHARMACEUTICAL, INC (COLL) Snapshot price: $33.265
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -30.10% | -1.00M |
$17.34 | -$17,340,000.00 | 2.32M |
Dec 8
| |||
Form 4
|
∞
| 3.32M |
$12.00 |
—
| 3.32M |
May 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CORCEPT THERAPEUTICS INC (CORT) Snapshot price: $22.02
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -21.50% | -3.00M |
—
|
—
| 10.96M |
Nov 28
| |||
Form 4
| -0.26% | -36.94K |
$9.34 | -$345,165.30 | 13.96M |
Nov 22 - Nov 25
| |||
Form 4
| -3.74% | -544.10K |
$9.56 | -$5,199,426.22 | 13.99M |
Nov 17 - Nov 21
| |||
Form 4
| -1.19% | -174.85K |
$9.55 | -$1,669,605.81 | 14.54M |
Nov 15 - Nov 16
| |||
Form 4
| +6.18% | 856.64K |
$4.05 | $3,469,408.20 | 14.71M |
Mar 30
| |||
Form 4
| +9.24% | 1.17M |
$4.29 | -$10.79 | 13.86M |
Mar 20 - Mar 24
| |||
Form 4
| -0.97% | -250.00K |
$4.10 | -$1,026,569.45 | 25.45M |
May 1 - May 2
| |||
Form 4
| -1.90% | -250.00K |
$4.28 | -$1,070,575.00 | 12.93M |
Apr 1
| |||
Form 4
| -0.63% | -250.00K |
$4.00 | -$1,000,818.05 | 39.74M |
Mar 5 - Mar 7
| |||
Form 4
| +6.81% | 856.64K |
$2.96 | $2,535,666.24 | 13.43M |
Mar 29
| |||
Form 4
| +6.34% | 750K |
$3.90 | $2,925,000.00 | 12.58M |
Jan 21
| |||
Form 4
| +7.81% | 856.64K |
$1.66 | $1,422,029.04 | 11.83M |
Apr 21
| |||
Form 4
| +28.72% | 2.45M |
$1.38 | $3,377,623.14 | 10.97M |
Oct 16
| |||
Form 4
| +119.67% | 4.64M |
$0.69 | $3,189,642.76 | 8.52M |
Feb 6
| |||
Form 4
| +9.90% | 349.43K |
$1.45 | $506,666.25 | 3.88M |
Nov 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Esperion Therapeutics, Inc. (ESPR) Snapshot price: $2.655
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -25.35% | -487.13K |
$32.78 | -$15,966,168.16 | 1.43M |
Nov 17 - Nov 18
| |||
Form 4
| -0.05% | -943.00 |
$30.00 | -$28,290.00 | 1.92M |
Oct 9
| |||
Form 4
| -0.62% | -11.93K |
$30.04 | -$358,289.49 | 1.92M |
Oct 7
| |||
Form 4
|
∞
| 1.93M |
$14.00 |
—
| 1.93M |
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||